Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026)
Oculis Holding AG's (OCS) quarterly Depreciation & Amortization (CF) came in at $196658.7 in Q1 2026, up 43.75% year-on-year from $136806.8 in Q1 2025, and down 0.52% quarter-over-quarter from $197684.8 in Q4 2025.
Oculis Holding AG (OCS) Depreciation & Amortization (CF) (2022 - 2026) Analysis & Trends
Oculis Holding AG's Depreciation & Amortization (CF) history runs 5 years deep, the most recent figure standing at $196658.7 for Q1 2026.
- On a quarterly basis, Depreciation & Amortization (CF) rose 43.75% year-over-year to $196658.7 in Q1 2026; TTM through Mar 2026 was $720851.8, a 39.89% increase from a year earlier, with the FY2025 full-year figure at $658546.2, up 42.7% from the prior year.
- Depreciation & Amortization (CF) declined to $196658.7 in Q1 2026 per OCS's latest filing, from $197684.8 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $207604.4 in Q4 2022 and bottomed at $33134.6 in Q3 2022.
- The 5-year median for Depreciation & Amortization (CF) is $136491.6 (2025), against an average of $125414.5.
- Biggest YoY gain for Depreciation & Amortization (CF) was 149.43% in 2023; the steepest drop was 59.82% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $207604.4 in 2022, then plunged by 59.82% to $83424.2 in 2023, then soared by 66.94% to $139265.7 in 2024, then soared by 41.95% to $197684.8 in 2025, then retreated by 0.52% to $196658.7 in 2026.
- Per Business Quant, the three latest OCS Depreciation & Amortization (CF) figures stand at $196658.7 (Q1 2026), $197684.8 (Q4 2025), and $190016.6 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 196,658.72 |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 41.14 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 55.90 Mn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 123.20 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 2.20 Mn |
| 10 | Alnylam Pharmaceuticals | 36.08 Bn | 33.07 Bn | 959.66 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 196,658.72 |
| Mar 31, 2026 | 196,658.72 |
| Dec 31, 2025 | 197,684.83 |
| Dec 31, 2025 | 197,684.83 |
| Sep 30, 2025 | 190,016.65 |
| Sep 30, 2025 | 190,016.65 |
| Jun 30, 2025 | 136,491.60 |
| Jun 30, 2025 | 136,491.60 |
| Mar 31, 2025 | 136,806.82 |
| Mar 31, 2025 | 136,806.82 |
| Dec 31, 2024 | 139,265.67 |
| Dec 31, 2024 | 139,265.67 |
| Sep 30, 2024 | 140,813.28 |
| Sep 30, 2024 | 140,813.28 |
| Jun 30, 2024 | 98,415.62 |
| Jun 30, 2024 | 98,415.62 |
| Mar 31, 2024 | 83,634.81 |
| Mar 31, 2024 | 83,634.81 |
| Dec 31, 2023 | 83,424.23 |
| Dec 31, 2023 | 83,424.23 |